The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 21, 2017
Filed:
Aug. 06, 2015
Applicant:
Vanderbilt University, Nashville, TN (US);
Inventors:
Heidi E. Hamm, Nashville, TN (US);
Shaun R. Stauffer, Nashville, TN (US);
Craig W. Lindsley, Brentwood, TN (US);
Wandong Wen, Nashville, TN (US);
Summer E. Young, Nashville, TN (US);
Matthew T. Duvernay, Nashville, TN (US);
Kayla J. Temple, Antioch, TN (US);
Assignee:
Vanderbilt University, Nashville, TN (US);
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/404 (2006.01); A61K 31/407 (2006.01); A61K 31/437 (2006.01); C07D 209/10 (2006.01); C07D 209/30 (2006.01); C07D 239/00 (2006.01); C07D 401/04 (2006.01); C07D 513/04 (2006.01); A61K 31/4985 (2006.01); A61K 31/519 (2006.01); A61K 31/5025 (2006.01); C07D 221/00 (2006.01); C07D 237/00 (2006.01); C08L 67/02 (2006.01); C08L 69/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/407 (2013.01); A61K 31/404 (2013.01); A61K 31/437 (2013.01); A61K 31/4985 (2013.01); A61K 31/5025 (2013.01); A61K 31/519 (2013.01); C07D 209/10 (2013.01); C07D 209/30 (2013.01); C07D 221/00 (2013.01); C07D 237/00 (2013.01); C07D 239/00 (2013.01); C07D 401/04 (2013.01); C07D 513/04 (2013.01); C08L 67/02 (2013.01); C08L 69/00 (2013.01); C08L 2205/02 (2013.01);
Abstract
Embodiments of the invention include substituted indole compounds and compositions thereof to inhibit protease activated receptor-4. Also described are methods of preparation of compositions and methods for treating diseases related to thrombotic disorders by administration of the composition.